JP2005536535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005536535A5 JP2005536535A5 JP2004529593A JP2004529593A JP2005536535A5 JP 2005536535 A5 JP2005536535 A5 JP 2005536535A5 JP 2004529593 A JP2004529593 A JP 2004529593A JP 2004529593 A JP2004529593 A JP 2004529593A JP 2005536535 A5 JP2005536535 A5 JP 2005536535A5
- Authority
- JP
- Japan
- Prior art keywords
- csfr
- csf
- agent
- pharmaceutical composition
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 28
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 claims 25
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 24
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 24
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims 24
- 239000003795 chemical substances by application Substances 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 241001465754 Metazoa Species 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 206010003246 arthritis Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 241000288906 Primates Species 0.000 claims 4
- 241000283984 Rodentia Species 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 210000004102 animal cell Anatomy 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 208000009386 Experimental Arthritis Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002950957A AU2002950957A0 (en) | 2002-08-23 | 2002-08-23 | A method of treatment and prophylaxis |
| AU2002951071A AU2002951071A0 (en) | 2002-08-29 | 2002-08-29 | A method of treatment and prophylaxis - II |
| PCT/AU2003/001078 WO2004017727A1 (en) | 2002-08-23 | 2003-08-22 | A method of treatment and prophylaxis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005536535A JP2005536535A (ja) | 2005-12-02 |
| JP2005536535A5 true JP2005536535A5 (enExample) | 2006-09-21 |
| JP4611738B2 JP4611738B2 (ja) | 2011-01-12 |
Family
ID=31947212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004529593A Expired - Fee Related JP4611738B2 (ja) | 2002-08-23 | 2003-08-22 | 治療および予防の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060093604A1 (enExample) |
| EP (1) | EP1542528B1 (enExample) |
| JP (1) | JP4611738B2 (enExample) |
| AT (1) | ATE443763T1 (enExample) |
| CA (1) | CA2496485C (enExample) |
| DE (1) | DE60329402D1 (enExample) |
| DK (1) | DK1542528T3 (enExample) |
| ES (1) | ES2333595T3 (enExample) |
| IL (1) | IL167060A (enExample) |
| NZ (1) | NZ538421A (enExample) |
| WO (1) | WO2004017727A1 (enExample) |
| ZA (1) | ZA200501629B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2056858T3 (da) | 2006-08-11 | 2014-09-29 | Csl Ltd | Behandling af lungesygdomstilstande |
| KR101750426B1 (ko) * | 2009-09-15 | 2017-06-23 | 씨에스엘 리미티드 | 신경 질환들의 치료 |
| US20110117092A1 (en) * | 2009-10-20 | 2011-05-19 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting g-csfr |
| EP3580236A4 (en) * | 2017-02-07 | 2020-12-09 | ME Therapeutics Inc. | ANTI-G-CSF ANTIBODIES AND ASSOCIATED USES |
| CN114755165B (zh) * | 2022-04-21 | 2024-11-22 | 重庆医科大学附属第二医院 | 一种用于检测g-csfr的流式检测试剂及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE66494B1 (en) * | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| AU635377B2 (en) * | 1989-11-21 | 1993-03-18 | University Of Melbourne, The | Anti-inflammatory compositions and methods |
| JP3525221B2 (ja) * | 1993-02-17 | 2004-05-10 | 味の素株式会社 | 免疫抑制剤 |
| US5420109A (en) * | 1993-11-12 | 1995-05-30 | Houghten Pharmaceuticals, Inc. | Cytokine restraining agents |
| AUPM375094A0 (en) * | 1994-02-08 | 1994-03-03 | Ludwig Institute For Cancer Research | Cytokine receptor interactive molecules and methods for assaying cytokine function |
| AUPM375194A0 (en) * | 1994-02-08 | 1994-03-03 | Ludwig Institute For Cancer Research | Cytokine receptor interactive molecules |
| US5902584A (en) * | 1994-02-08 | 1999-05-11 | Ludwig Institute For Cancer Research | Antibodies which bind the G-CSF receptor extracelluar domain and methods of treatment |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US6716811B1 (en) * | 2000-07-20 | 2004-04-06 | Affymax, Inc. | Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses |
| EP1317537B1 (en) * | 2000-09-08 | 2006-12-20 | Massachusetts Institute Of Technology | G-csf analog compositions and methods |
-
2003
- 2003-08-22 CA CA2496485A patent/CA2496485C/en not_active Expired - Fee Related
- 2003-08-22 DE DE60329402T patent/DE60329402D1/de not_active Expired - Lifetime
- 2003-08-22 JP JP2004529593A patent/JP4611738B2/ja not_active Expired - Fee Related
- 2003-08-22 DK DK03792044.4T patent/DK1542528T3/da active
- 2003-08-22 NZ NZ538421A patent/NZ538421A/en not_active IP Right Cessation
- 2003-08-22 AT AT03792044T patent/ATE443763T1/de not_active IP Right Cessation
- 2003-08-22 ES ES03792044T patent/ES2333595T3/es not_active Expired - Lifetime
- 2003-08-22 EP EP03792044A patent/EP1542528B1/en not_active Expired - Lifetime
- 2003-08-22 US US10/525,363 patent/US20060093604A1/en not_active Abandoned
- 2003-08-22 WO PCT/AU2003/001078 patent/WO2004017727A1/en not_active Ceased
-
2005
- 2005-02-23 IL IL167060A patent/IL167060A/en active IP Right Grant
- 2005-02-24 ZA ZA2005/01629A patent/ZA200501629B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Resident memory B cells in barrier tissues | |
| Sun et al. | Integration of RNAi and RNA-seq reveals the immune responses of Epinephelus coioides to sigX gene of Pseudomonas plecoglossicida | |
| Hirahara et al. | Helper T‐cell differentiation and plasticity: insights from epigenetics | |
| ES2685790T3 (es) | Ratones humanizados con M-CSF | |
| Kazenwadel et al. | A Prox1 enhancer represses haematopoiesis in the lymphatic vasculature | |
| JP2017514501A5 (enExample) | ||
| Kim et al. | Middle East respiratory syndrome-coronavirus infection into established hDPP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis | |
| Vodovotz et al. | The hepatocyte as a microbial product-responsive cell | |
| CN112662669A (zh) | 一种Il21基因敲除小鼠模型及其构建方法、应用 | |
| US20210121530A1 (en) | Methods and compositions for regulating innate lymphoid cell inflammatory responses | |
| JP2009525046A5 (enExample) | ||
| Suzuki et al. | Identical sets of methylated and nonmethylated genes in Ciona intestinalis sperm and muscle cells | |
| Bam et al. | Spontaneous cutaneous papillomatosis in yaks and detection and quantification of bovine papillomavirus‐1 and‐2 | |
| Pfankuche et al. | Reduced angiogenic gene expression in morbillivirus‐triggered oncolysis in a translational model for histiocytic sarcoma | |
| CN110484615A (zh) | lncRNA在病毒性心肌炎中调控巨噬细胞极化的应用 | |
| JP2023534035A (ja) | ＳＡＲＳ－ＣｏＶ－２感染のためのヒト化マウスモデル | |
| RU2377248C2 (ru) | Устойчивые к грибкам растения и их использование | |
| JP2021508236A5 (enExample) | ||
| Bello-Perez et al. | Neutralization of viral infectivity by zebrafish c-reactive protein isoforms | |
| JP2005536535A5 (enExample) | ||
| US9655947B2 (en) | Use of a granulin or a granulin-like compound for the therapy or prophylaxis of chronic pain | |
| CN113699152A (zh) | Slc35e2b基因敲除小鼠动物模型的构建方法和应用 | |
| CN116784280B (zh) | 一种tfrc人源化小鼠模型的构建方法及其应用 | |
| JP2009509544A5 (enExample) | ||
| CN118910165A (zh) | 一种cxcl16基因人源化动物模型的构建方法及应用 |